Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

P. Denton, Christopher; A. Merkel, Peter; E. Furst, Daniel; Khanna, Dinesh; Emery, Paul; M. Hsu, Vivien; Silliman, Nancy; Streisand, James; Powell, John; Åkesson, Anita; Coppock, John; van den Hoogen, Frank; Herrick, Ariane; D. Mayes, Maureen; Veale, Douglas; Haas, Joanna; Ledbetter, Stephen; H. Korn, Joseph; M. Black, Carol; R. Seibold, James; Behalf Of The Cat‐192 Study Group The Scleroderma Clinical Trials Consortium, on

doi:10.1002/art.22289

Public

Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192

Shared by NobleBlocks on Jan 1, 2007 • 12:00 AM UTC

Authors:

Christopher P. Denton

Peter A. Merkel

Daniel E. Furst

Abstract

Abstract Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic sclerosis (dcSSc). Methods Patients with SSc duration of <18 months were randomly assigned to the placebo group or t...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!